Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-cash Items (2016 - 2022)

Historic Non-cash Items for Spyre Therapeutics (SYRE) over the last 8 years, with Q4 2022 value amounting to $2000.0.

  • Spyre Therapeutics' Non-cash Items fell 9939.02% to $2000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $2000.0, marking a year-over-year decrease of 9939.02%. This contributed to the annual value of $2000.0 for FY2022, which is 9939.02% down from last year.
  • Per Spyre Therapeutics' latest filing, its Non-cash Items stood at $2000.0 for Q4 2022, which was down 9939.02% from $328000.0 recorded in Q4 2021.
  • Over the past 5 years, Spyre Therapeutics' Non-cash Items peaked at $4.8 million during Q4 2018, and registered a low of $2000.0 during Q4 2022.
  • For the 5-year period, Spyre Therapeutics' Non-cash Items averaged around $2.5 million, with its median value being $3.6 million (2019).
  • Per our database at Business Quant, Spyre Therapeutics' Non-cash Items skyrocketed by 9331.18% in 2018 and then crashed by 9939.02% in 2022.
  • Spyre Therapeutics' Non-cash Items (Quarter) stood at $4.8 million in 2018, then fell by 24.09% to $3.6 million in 2019, then rose by 4.01% to $3.8 million in 2020, then crashed by 91.34% to $328000.0 in 2021, then plummeted by 99.39% to $2000.0 in 2022.
  • Its last three reported values are $2000.0 in Q4 2022, $328000.0 for Q4 2021, and $3.8 million during Q4 2020.